BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shivaji UN, Nardone OM, Cannatelli R, Smith SC, Ghosh S, Iacucci M. Small molecule oral targeted therapies in ulcerative colitis. Lancet Gastroenterol Hepatol 2020;5:850-61. [PMID: 32171056 DOI: 10.1016/S2468-1253(19)30414-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Li C, Wang J, Ma R, Li L, Wu W, Cai D, Lu Q. Natural-derived alkaloids exhibit great potential in the treatment of ulcerative colitis. Pharmacol Res 2021;175:105972. [PMID: 34758401 DOI: 10.1016/j.phrs.2021.105972] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Nardone OM, de Sire R, Petito V, Testa A, Villani G, Scaldaferri F, Castiglione F. Inflammatory Bowel Diseases and Sarcopenia: The Role of Inflammation and Gut Microbiota in the Development of Muscle Failure. Front Immunol 2021;12:694217. [PMID: 34326845 DOI: 10.3389/fimmu.2021.694217] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Magro F, Estevinho MM. Is tofacitinib a game-changing drug for ulcerative colitis? United European Gastroenterol J 2020;8:755-63. [PMID: 32552501 DOI: 10.1177/2050640620935732] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
4 Nielsen OH, Boye TL, Chakravarti D, Gubatan J. Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease. Trends Pharmacol Sci 2022:S0165-6147(22)00032-3. [PMID: 35277286 DOI: 10.1016/j.tips.2022.02.008] [Reference Citation Analysis]
5 Wang L, Hu Y, Song B, Xiong Y, Wang J, Chen D. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease. Inflamm Res 2021;70:753-64. [PMID: 34212215 DOI: 10.1007/s00011-021-01482-x] [Reference Citation Analysis]
6 Rong Y, Hong G, Zhu N, Liu Y, Jiang Y, Liu T. Photodynamic Therapy of Novel Photosensitizer Ameliorates TNBS-Induced Ulcerative Colitis via Inhibition of AOC1. Front Pharmacol 2021;12:746725. [PMID: 34744725 DOI: 10.3389/fphar.2021.746725] [Reference Citation Analysis]
7 Honjo H, Watanabe T, Kamata K, Minaga K, Kudo M. RIPK2 as a New Therapeutic Target in Inflammatory Bowel Diseases. Front Pharmacol 2021;12:650403. [PMID: 33935757 DOI: 10.3389/fphar.2021.650403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Li Y, Chen J, Bolinger AA, Chen H, Liu Z, Cong Y, Brasier AR, Pinchuk IV, Tian B, Zhou J. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021;27:S38-62. [PMID: 34791293 DOI: 10.1093/ibd/izab190] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Pan X, Wang H, Zheng Z, Huang X, Yang L, Liu J, Wang K, Zhang Y. Pectic polysaccharide from Smilax china L. ameliorated ulcerative colitis by inhibiting the galectin-3/NLRP3 inflammasome pathway. Carbohydr Polym 2022;277:118864. [PMID: 34893269 DOI: 10.1016/j.carbpol.2021.118864] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
10 Liu WY, Chien CW, Tung TH. Healthcare practice strategies for integrating personalized medicine: Management of COVID-19. World J Clin Cases 2021; 9(29): 8647-8657 [PMID: 34734043 DOI: 10.12998/wjcc.v9.i29.8647] [Reference Citation Analysis]